Neurol. praxi. 2020;21(1):41-45 | DOI: 10.36290/neu.2020.024

Pharmacotherapy of non-Alzheimer's types of dementia

doc. MUDr. Martin Vališ, Ph.D., prof. MUDr. Jiří Masopust, Ph.D., MUDr. Zbyšek Pavelek, Ph.D.
Neurologická klinika LF a FN Hradec Králové

The review deals with pharmacotherapy for less common dementia - frontotemporal dementia, dementia with Lewy bodies, Parkinson's disease dementia, and vascular dementia. Cholinesterase inhibitors and memantine and their pharmacodynamics and side effects are mentioned. They differ among themselves in the degree of evidence for efficacy in individual types of dementia, dosage, pharmacodynamics, and adverse effects. In addition to pharmacotherapy, it is important to include non-pharmacological approaches in the treatment of dementia, to deploy suitable drugs in time, to adequately dose and develop new molecules for the treatment of these diseases. All this presents new challenges for researchers in their further research on the development of new drugs and therapeutic strategies.

Keywords: dementia, vascular dementia, dementia with Lewy bodies, frontotemporal dementia, Parkinson's disease dementia.

Published: March 30, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vališ M, Masopust J, Pavelek Z. Pharmacotherapy of non-Alzheimer's types of dementia. Neurol. praxi. 2020;21(1):41-45. doi: 10.36290/neu.2020.024.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alzheimer's Association. Alzheimer's Association Report 2015. Alzheimer's disease facts and figures. Alzheimer's & Dementia 2015; 11: 332-384. Go to original source... Go to PubMed...
    2. Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet 2015; 386(10004): 1672-1682. Go to original source...
    3. Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, Pourcher E, Gray J, Thomas G, Swartz J, Hsu T, Moline ML. Donepezil in Parkinson's disease dementia: a randomized, double-blind effi cacy and safety study. Mov Disord 2012; 27: 1230-1238. Go to original source... Go to PubMed...
    4. Emre M, Poewe W, De Deyn PP, Barone P, Kulisevsky J, Pourcher E, van Laar T, Storch A, Micheli F, Burn D, Durif F, Pahwa R, Callegari F, Tenenbaum N, Strohmaier C. Long-term safety of rivastigmine in Parkinson disease dementia: an open-label, randomized study. Clin Neuropharmacol 2014; 37: 9-16. doi: 10.1097/WNF.0000000000000010. Go to original source... Go to PubMed...
    5. Guekht AB, Moessler H, Novak PH, Gusev EI. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis 2010; 20: 310-318. Go to original source...
    6. Chen N, Yang M, Guo J, Zhou M, Zhu C, He L. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev 2013; 1: CD008900. Go to original source...
    7. Cheng ST, Chow PK, Song YQ, Yu EC, Chan AC, Lee TM, Lam JH. Mental and physical activities delay cognitive decline in older persons with dementia. Am J Geriatr Psychiatry 2014; 22(1): 63-74. Go to original source...
    8. Jones DR, Moussaud S, McLean P. Targeting heat shock proteins to modulate α-synuclein toxicity. Ther Adv Neurol Disord 2014; 7: 33-51. Go to original source... Go to PubMed...
    9. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007; 6(9): 782-792. Go to original source...
    10. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 2004; (1): CD004395. Go to original source...
    11. Masopust J, Protopopová D, Vališ M, Pavelek Z, Klímová B. Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: a review. Neuropsychiatr Dis Treat. 2018; 14: 1211-1220. Go to original source...
    12. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev 2016; (1): CD003160. Go to original source...
    13. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017; 89(1): 88-100. Go to original source... Go to PubMed...
    14. O'Brien JT, Thomas A. Vascular dementia. Lancet 2015; 386(10004): 1698-706. Go to original source...
    15. Pearce LA, McClure LA, Anderson DC, Jacova C, Sharma M, Hart RG, Benavente OR; SPS3 Investigators. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurol 2014; 13: 1177-1185. Go to original source...
    16. Rusina R, Matěj R, et al. Neurodegenerativní onemocnění. Praha: Mladá fronta 2014: 351.
    17. Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C; and the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. Mov Disord 2019; 34(2): 180-198. Go to original source... Go to PubMed...
    18. Shivanand P. Review on Alzheimer's disease: its cause, symptoms, and treatment at worldwide. International Journal of Applied Biology and Pharmaceutical Technology 2009; 1(1): 112-120.
    19. Šonka K. Porucha chování v REM spánku. Neurol. praxi, 2008; 9(5): 297-299.
    20. Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13th ed. West Sussex, United Kingdom: John Wiley & Sons 2018; 854.
    21. Tsai RM, Boxer AL. Therapy and clinical trials in frontotemporal dementia: past, present, and future. J Neurochem. 2016; 138(Suppl 1): 211-221. Go to original source... Go to PubMed...
    22. Youdim MB, Oh YJ. Promise of neurorestoration and mitochondrial biogenesis in Parkinson's disease with multi target drugs: an alternative to stem cell therapy. Exp Neurobiol 2013; 22: 167-72. Go to original source... Go to PubMed...
    23. Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet 2015; 386(10004): 1683-1697. Go to original source...
    24. WHO 2017. http://www.who.int/features/factfiles/dementia/en/.

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.